Na Xu

2.2k total citations
98 papers, 841 citations indexed

About

Na Xu is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Na Xu has authored 98 papers receiving a total of 841 indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Hematology, 33 papers in Genetics and 19 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Na Xu's work include Chronic Myeloid Leukemia Treatments (34 papers), Hematopoietic Stem Cell Transplantation (31 papers) and Acute Myeloid Leukemia Research (31 papers). Na Xu is often cited by papers focused on Chronic Myeloid Leukemia Treatments (34 papers), Hematopoietic Stem Cell Transplantation (31 papers) and Acute Myeloid Leukemia Research (31 papers). Na Xu collaborates with scholars based in China, United States and Myanmar. Na Xu's co-authors include Qifa Liu, Fen Huang, Zhiping Fan, Li Xuan, Jing Sun, Ren Lin, Jieyu Ye, Yu Wang, Xiao‐Jun Huang and Hongsheng Zhou and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Na Xu

87 papers receiving 836 citations

Peers

Countries citing papers authored by Na Xu

Since Specialization

Citations

This map shows the geographic impact of Na Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Na Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Na Xu more than expected).

Fields of papers citing papers by Na Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Na Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Na Xu. The network helps show where Na Xu may publish in the future.

Co-authorship network of co-authors of Na Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Na Xu. A scholar is included among the top collaborators of Na Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Na Xu. Na Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dynamic forecasting module for chronic graft-versus-host disease progression based on a disease-associated subpopulation of B cells: a multicenter prospective study 2025 ·EBioMedicine ·Yuanchen Ma, Jieying Chen, Zhiping Fan, Jiahao Shi, Gang Li, Xiaobo Li, Tao Wang, Na Xu, Jia-Ling Liu, Zhishan Li, (unknown), Xiaoran Zhang, Dongjun Lin, Song Wu, Qifa Liu, (unknown), Xiaoyong Chen, Andy Peng Xiang	0
2	Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial 2025 ·Journal of Translational Medicine ·Bailin He, Ren Lin, Na Xu, Le Qin, Zhixiang Wang, Qiang Wang, Xiaofang Li, Xiaolei Wei, Yongqiang Wei, Zhaoyang Tang, (unknown), Fen Huang, Xiaoli Liu, Jing Sun, Li Xuan, Peng Li, Hongsheng Zhou, Qifa Liu	4
3	Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial 2025 ·The Lancet Regional Health - Western Pacific ·Qifa Liu, (unknown), Na Xu, (unknown), (unknown), Fen Huang, Ren Lin, Hua Jin, (unknown), (unknown), (unknown), Guopan Yu, Pengcheng Shi, Ruijuan Sun, Xiaojun Xu, (unknown), (unknown), Jing Sun, Yu Wang, Li Xuan	1
4	Intensified conditioning containing decitabine versus standard myeloablative conditioning for adult patients with KMT2A-rearranged leukemia: a multicenter retrospective study 2024 ·BMC Medicine ·(unknown), (unknown), Shiqi Liu, (unknown), Ying Dong, Zhiping Fan, Yiqing Li, Fen Huang, Na Xu, Can Liu, (unknown), (unknown), Ren Lin, Hua Jin, Xiong Zhang, Ruijuan Sun, Qifa Liu, Li Xuan	2
5	Metagenomic Next-Generation Sequencing in the Diagnosis of Pulmonary Infections after Allogeneic Hematopoietic Stem Cell Transplantation 2024 ·Transplantation and Cellular Therapy ·Rong Fu, Jun Xu, (unknown), (unknown), (unknown), Wenjie Xiong, Fen Huang, Li Xuan, Na Xu, Hui Liu, Zhixiang Wang, Jing Sun, (unknown), Ren Lin	1
6	Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study 2023 ·Blood ·Guopan Yu, Yu Zhang, Hua Jin, (unknown), (unknown), Sijian Yu, Na Xu, Xin Du, Dongjun Lin, Jie Xiao, Zhiqiang Sun, Hongyu Zhang, Xinquan Liang, Ziwen Guo, Weihua Zhao, Min Dai, Xuejie Jiang, Li Xuan, Pengcheng Shi	0
7	Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate‐risk acute myeloid leukemia in first complete remission undergoing auto‐HSCT: An open‐label, multicenter, randomized phase 3 trial 2023 ·American Journal of Hematology ·Hui Liu, Fen Huang, Yu Zhang, Meiqing Wu, Na Xu, Zhiping Fan, Zhiqiang Sun, Xudong Li, Dongjun Lin, (unknown), Xiaodan Liu, (unknown), Pengcheng Shi, Jun Xu, Zhixiang Wang, (unknown), Jing Sun, Qifa Liu, Li Xuan	0
8	Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20–a very high-risk subtype in B-cell acute lymphoblastic leukemia 2022 ·Bone Marrow Transplantation ·(unknown), (unknown), Zhixiang Wang, (unknown), (unknown), Qiuli Li, (unknown), (unknown), Xuan Zhou, Ren Lin, Na Xu, Zhiping Fan, Fen Huang, Jing Sun, Xiaoli Liu, Qifa Liu, Hongsheng Zhou	6
9	Allogeneic Stem Cell Transplantation Combined With Transfusion of Mesenchymal Stem Cells in Primary Myelofibrosis: A Multicenter Retrospective Study 2022 ·Frontiers in Oncology ·Qingyuan Wang, Na Xu, Yu Wang, Xi Zhang, Limin Liu, Huifen Zhou, Hong Wang, Xiang Zhang, Xiaowen Tang, Chengcheng Fu, Miao Miao, Depei Wu	5
10	Haploidentical donor transplant is associated with secondary poor graft function after allogeneic stem cell transplantation: A single‐center retrospective study 2021 ·Cancer Medicine ·(unknown), (unknown), Jun Xu, Zhiping Fan, Fen Huang, Na Xu, Li Xuan, (unknown), Hui Liu, Zhixiang Wang, Jing Sun, Qifa Liu	8
11	A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells 2020 ·Biomedicine & Pharmacotherapy ·Bailin He, Qiang Wang, Xiaoli Liu, Ziyuan Lu, Jiaochan Han, (unknown), Bing Z. Carter, Qifa Liu, Na Xu, Hongsheng Zhou	18
12	A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study 2020 ·Leukemia ·Hui Liu, Li Xuan, Ren Lin, Lan Deng, Zhiping Fan, Danian Nie, Xudong Li, Xinquan Liang, Dan Xu, Yu Zhang, Na Xu, Jieyu Ye, Hua Jin, Dongjun Lin, Liping Ma, Jing Sun, Fen Huang, Qifa Liu	12
13	Cytomegalovirus Infection in Bone Marrow-Derived Mesenchymal Stem Cells: Implications for Functions and Exploration of Relevant Mechanisms 2019 ·Blood ·(unknown), Zhiping Fan, Fen Huang, Na Xu, Li Xuan, Ren Lin, Ke Zhao, Qifa Liu	1
14	The Effect of Sorafenib Therapy on the Outcome of Acute Myeloid Leukemia with FLT3-ITD Undergoing Allogeneic Hematopoietic Stem Cell Transplantation 2017 ·Blood ·Li Xuan, Yu Wang, Fen Huang, Bingyi Wu, Zhiping Fan, Na Xu, Jieyu Ye, Jing Sun, Xiao‐Jun Huang, Qifa Liu	0
15	Tumor-Derived LOXL2 Is Highly Expressed in Myelofibrosis and Activating Mesenchymal Stem Cells Differentiate into Cancer Associated Fibroblasts In Vitro 2017 ·Blood ·Na Xu, (unknown), Xuan Zhou, (unknown), (unknown), (unknown), Jing Sun, (unknown)	1
16	Chidamide, a Novel Histone Deacetylase Inhibitor, Combined with Imatinib Induces Synthetic Lethality in Drug-Resistant Chronic Myeloid Leukemia 2017 ·Blood ·(unknown), Qiang Wang, Na Xu, Ziyuan Lu, (unknown), Jing Sun, Hongsheng Zhou, Xiaoli Liu	1
17	Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia 2017 ·Journal of Experimental & Clinical Cancer Research ·Ziyuan Lu, Na Xu, (unknown), (unknown), (unknown), Hongsheng Zhou, Xiaoli Liu	42
18	Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation 2016 ·OncoImmunology ·Xinmiao Jiang, Lan‐Ping Xu, Yu Zhang, Fen Huang, Dai‐Hong Liu, Jin Sun, Chaoyang Song, Xinquan Liang, Zhiping Fan, Hongsheng Zhou, Min Dai, Can Liu, Qianli Jiang, Na Xu, Li Xuan, Meiqing Wu, Xiao‐Jun Huang, Qifa Liu	19
19	EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins 2016 ·International Journal of Medical Sciences ·Lin Li, Na Xu, Jinfang Zhang, (unknown), Xuan Zhou, (unknown), Yuling Li, Xiaoli Liu	8
20	EphB4-VAV1 signaling pathway is associated with imatinib resistance in chronic myeloid leukemia cells 2016 ·Blood Cells Molecules and Diseases ·Jinfang Zhang, Na Xu, Qingfeng Du, Rong Li, Xiaoli Liu	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact